Accord Healthcare, Inc. received approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) 090121, providing a generic alternative to finasteride oral tablets. The approval is expected to enhance market competition and create new opportunities for Accord Healthcare, potentially driving volume growth in the generic 5-alpha-reductase inhibitor segment.